Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.
Association between proto-oncogene N-RAS transcript level and overall survival in node-negative muscle-invasive urothelial bladder carcinoma.
FMC-220 is a first-in-class covalent activator of p53 Y220C designed to address potency and tolerability challenges of non-covalent approaches In preclinical studies, FMC-220 demonstrated ...
New Drug Research & Development Co. Ltd. has disclosed cellular tumor antigen p53 (TP53) (Y220C mutant) stabilizers reported to be useful for the treatment of cancer.
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and ...
It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. Receive News & Ratings for PMV ...
The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback